Faculty Collaboration Database

Device therapy and cardiac transplantation for end-stage heart failure. Curr Probl Cardiol 2010 Jan;35(1):8-64

Date

12/08/2009

Pubmed ID

19962044

DOI

10.1016/j.cpcardiol.2009.09.001

Scopus ID

2-s2.0-70749149441 (requires institutional sign-in at Scopus site)   47 Citations

Abstract

The prevalence of heart failure is increasing, and the prognosis of end-stage heart failure remains dismal. The gold-standard therapy in end-stage heart failure remains cardiac transplantation at the present time, but there is a great excess of eligible candidates compared with the number of donor organs. Advances in mechanical support, the development of the left ventricular assist device (LVAD), and the total artificial heart has reduced mortality and morbidity in patients awaiting transplantation, and LVADs are now approved as an strategy for destination therapy. Miniaturization, increased device durability, and complete implantability may render LVADs an option in earlier stages of heart failure, as a bridge to myocardial recovery or even as a viable alternative to transplantation. Alternative strategies under investigation are cell therapy and xenotransplantation. In the present article, current and potential future therapeutic options in end-stage heart failure are reviewed.

Author List

Boilson BA, Raichlin E, Park SJ, Kushwaha SS

Author

Eugenia Raichlin MD Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Graft Rejection
Heart Failure
Heart Transplantation
Heart, Artificial
Heart-Assist Devices
Humans
Male
Middle Aged
Patient Selection
Postoperative Complications
Prevalence
Tissue Donors